Key facts
- Umecrine Cognition’s last known valuation is $71.5M (Jul 2021).
- It has raised $28.1M; the latest was Later Stage VC ($5.5M) in Jul 2025.
- Notable investors include Almi Invest, Norrlandsfonden, AB Ility, Fort Knox, KDventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Umecrine Cognition
- ·The full record, as it builds
Funding rounds
No funding rounds for Umecrine Cognition are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Umecrine Cognition
Developer of pharmaceutical drugs designed to treat cognitive neurological disorders. The company offers drugs for the treatment of symptoms in the central nervous system related to chronic neuroinflammation, a brain distortion that can lead to severely impaired cognition and fatigue, enabling healthcare industries to directly address the neurocognitive signs and symptoms of hepatic encephalopathy.
- Sector
- Healthcare
- HQ
- Solna, Sweden
- Founded
- 2006
- Employees
- 3
- Website
- umecrinecognition.com/
- Ownership
- Privately Held (backing)
Umecrine Cognition doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Umecrine Cognition shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Umecrine Cognition in its N-PORT filings yet. We sweep new filings monthly.